Back to All Resources

IRAK4 degraders for MYD88 mutant lymphoma

June 18, 2019

International Conference on Malignant Lymphoma (ICML)

Area of Focus

Oncology

Programs

IRAKIMiD (KT-413)

Indications

MYD88 Tumors

Development Stage

Pre-clinical Data

Share

You may also be interested in these resources

August 24, 2022

Discovery and characterization of potent degraders of IRAK4 and IMiD substrates for oncology indications

ACS Fall 2022

June 26, 2022

Discovery of IRAKIMiDs: Dual-Mechanism Degraders Targeting IRAK4 and IMiDSubstrates for Oncology

37th ACS National Medicinal Chemistry Symposium